Novo Nordisk parent’s huge manufacturing deal is one step closer to closing. Meanwhile, Nobel Prize winners urge senators to ...

Wegovy and other GLP-1 medications have become extremely popular over the past few years. Novo Nordisk (which makes both ...

The proposed buyout of contract drug manufacturer Catalent won’t raise competition concerns, the European Commission said.

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

In the U.S., the chorus of opposition against the proposed buyout continues to grow and now includes the CEOs of Roche and ...

Market multiples for Novo Nordisk are also attractive now, especially with a forward P/E for 2025 at 28.3x. Learn more about NVO stock here.

Evotec and Novo Nordisk launched LAB eN² in September 2023 to nurture early research from academic institutions into novel therapeutics.

Novo will drop its U.S. list price for its Fiasp by 75% and for Tresiba by 72%, the Danish company said in a release. The new ...

Danish drug maker Novo Nordisk said on Thursday it will reduce the U.S. list prices of two insulin products by more than 70% ...

Few companies garner as much reliable attention as Novo Nordisk ( NVO) does these days. With a bull market coinciding with a ...

Amid a multi-year, multibillion-dollar spending spree to scale its global manufacturing capacity, Novo Nordisk is laying down ...

Eli Lilly's popular weight-loss drug Zepbound outperformed Danish drugmaker Novo Nordisk's Wegovy in a clinical trial, ...